Categories: News

Kraig Biocraft Laboratories Sets New World Record for Largest Spider Silk Gene Insert into Silkworm

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ANN ARBOR, Mich., March 24, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk biotechnology, today announced a groundbreaking scientific achievement in the development of high-performance biomaterials. Kraig Labs successfully engineered the largest known spider silk gene insert into silkworm—nearly doubling the previous record. This breakthrough represents a major step toward creating next-generation spider silk fibers with enhanced strength, flexibility, and performance potential.

The project was led by Dr. Xiaoli Zhang, the Company’s research manager, whose team continues to push the boundaries of genetic engineering for spider silk production.

“This milestone significantly expands the possibilities for spider silk technology,” said Dr. Zhang. “By increasing the size of the inserted spider silk genes, we are unlocking the potential for new materials with properties beyond what is currently achievable. This breakthrough lays the foundation for the future of high-performance silk fibers.”

While the sheer size of the genetic insert marks a scientific breakthrough, its real significance is not in its size but in the information this genetic packet carries. This allows for the creation of larger more complex proteins with unique mechanical properties for incorporation into the silk fibers. As Kraig Labs moves forward with this technology, the Company will explore the tremendous opportunities for increases in material performance these new larger packets allow.

This scientific accomplishment represents a bold step forward in material innovation and expands the possibilities of what can be achieved in material performance. Kraig Labs remains fully committed to the commercialization of its current recombinant spider silk production strains, even as it accelerates its development of more advanced materials. The Company is moving forward rapidly to advance the scale-up of its existing technologies, bringing spider silk fibers to market for applications in performance textiles, defense, and industrial sectors.

“Our mission is twofold: to commercialize our existing spider silk technology while continuously innovating for the future,” said Company CEO and founder, Kim Thompson. “This record-setting genetic achievement underscores the depth of our research capabilities and demonstrates our long-term vision for creating even more advanced biomaterials. Dr. Zhang and her team have taken a critical step toward making the next generation of spider silk a reality.”

Kraig Labs is currently accelerating its recombinant spider silk production, while also investing in the future of spider silk technology. The Company will continue to provide updates on both its commercialization efforts and its groundbreaking research.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0ab1f7d4-8e0a-4ccb-8411-068ff1fa388a

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

15 hours ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

15 hours ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

15 hours ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

15 hours ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

15 hours ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

15 hours ago